The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells

Neoplasia

Volumn 6, Issue 3, 2004, Pages 187-194

  Watts, George S ^a   Oshiro, Marc M ^a   Junk, Damian J ^a   Wozniak, Ryan J ^a   Watterson, Summer J ^a   Domann, Frederick E ^b   Futscher, Bernard W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acetyltransferase; Microarray; P300 CBP associated factor; P53; PCAF

Indexed keywords

DOXORUBICIN; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN P53; SMALL INTERFERING RNA;

ACETYLATION; ARTICLE; BREAST TUMOR; CHROMATIN; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG MECHANISM; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

EID: 2442672704     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.3292     Document Type: Article

References (23)

1. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
2. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
3. Gu W and Roeder RG (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
4. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, and Berger SL (1999). p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19, 1202-1209.
5. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, and Appella E (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12, 2831-2841.
6. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y, and Evans RM (1999). A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96, 393-403.
7. Trievel RC, Li FY, and Marmorstein R (2000). Application of a fluorescent histone acetyltransferase assay to probe the substrate specificity of the human p300/CBP-associated factor. Anal Biochem 287, 319-328.
8. Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez L, Domann J, and Futscher FE (2003). Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22, 3624-3634.
9. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, and Nakatani Y (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959.
10. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, and Nakatani Y (1996). A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382, 319-324.
11. Liu Y, Colosimo AL, Yang XJ, and Liao D (2000). Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol Cell Biol 20, 5540-5553.
12. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B (1997). A model for p53-induced apoptosis. Nature 389, 300-305.
13. Meltzer P, Leibovitz A, Dalton W, Villar H, Kute T, Davis J, Nagle R, and Trent J (1991). Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br J Cancer 63, 727-735.
14. Thompson F, Emerson J, Dalton W, Yang JM, McGee D, Villar H, Knox S, Massey K, Weinstein R, and Bhattacharyya A (1993). Clonal chromosome abnormalities in human breast carcinomas: I. Twenty-eight cases with primary disease. Genes Chromosomes Cancer 7, 185-193.
15. Trent J, Yang JM, Emerson J, Dalton W, McGee D, Massey K, Thompson F, and Villar H (1993). Clonal chromosome abnormalities in human breast carcinomas: II. Thirty-four cases with metastatic disease. Genes Chromosomes Cancer 7, 194-203.
16. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, and Vogelstein B (1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95, 2509-2514.
17. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, and Lu H (2001). cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 299, 434-441.
18. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, and Vogelstein B (1992). Definition of a consensus binding site for p53. Nat Genet 1, 45-49.
19. Ellison G, Klinowska T, Westwood RFR, Docter E, French T, and Fox JC (2002). Further evidence to support the melanocytic origin of MDA-MB-435. J Clin Pathol 55, 294-299.
20. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, and Weinstein JN (2000). A Gene Expression database for the molecular pharmacology of cancer. Nature 24, 236-244.
21. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, and Berger SL (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8, 1243-1254.
22. Espinosa JM and Emerson BM (2001). Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8, 57-69.
23. Jin Y, Zeng SX, Dai MS, Yang XJ, and Lu H (2002). MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 277, 30838-30843.